NCT02651545View on ClinicalTrials.gov

Effects of Teriflunomide (Aubagio) on Cognitive and Vocational Outcomes in Multiple Sclerosis

CompletedOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

November 30, 2020

Study Completion Date

November 30, 2020

Conditions
Multiple Sclerosis
Trial Locations (1)

14203

Buffalo General Hospital, D3, Buffalo

All Listed Sponsors
lead

State University of New York at Buffalo

OTHER

NCT02651545 - Effects of Teriflunomide (Aubagio) on Cognitive and Vocational Outcomes in Multiple Sclerosis | Biotech Hunter | Biotech Hunter